Radioligand Therapy Market

The radioligand therapy market is expected to grow significantly in the coming years as the incidence of cancer and other related diseases rises, as demand for targeted therapies rises, and R&D investments rise.Advances in technology and rising adoption of radioligand therapy in the treatment of various cancers such as prostate cancer, neuroendocrine tumours, and somatostatin receptor-positive tumours are also driving the market.Novartis AG, GE Healthcare, Eckert & Ziegler BEBIG, IBA Molecular, and Nordion are among the major players in the radioligand therapy market (Curtis-Wright).

Advanced Accelerator Applications, Positron Corporation, and Eckert & Ziegler Isotope Products are some of the market's other major players. The radioligand therapy market was worth USD ** billion in 2019 and is expected to grow at a CAGR of **% between 2018 and 2031.

The major market drivers are rising cancer incidence, increased adoption of targeted therapy, and rising demand for personalised medicine.Novartis AG, GE Healthcare, Eckert & Ziegler BEBIG, Eckert & Ziegler Isotope Products, Eckert & Ziegler Strahlen- und Medizintechnik AG, IBA Molecular, and others are among the market's major players.